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Hodgkin lymphomaBone marrow involvement in lymphoma may have prognostic and therapeutic consequences. Bone marrow bi-
opsy (BMB) is the establishedmethod for the evaluation of the bonemarrow. 18F-ﬂuoro-2-deoxy-D-glucose pos-
itron emission tomography (FDG-PET) plays an important role in lymphoma staging, but its value in the
assessment of the bone marrow and whether it can replace BMB is still a topic of debate and investigation. The
purpose of this scientiﬁc communication is to provide an evidence-based overview about the opportunities
and limitations of BMB and FDG-PET in the evaluation of the bone marrow in patients with lymphoma. This ar-
ticleﬁrst reviews the basic properties, opportunities and limitations of BMB and bonemarrow FDG-PET, and then
focuses on the clinical utility of BMB and bone marrow FDG-PET in three major lymphoma subtypes including
Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
The bone marrow is an important anatomical site where lympho-
matous cells can reside. Detection of lymphomatous bone marrow
involvement may be clinically relevant from several perspectives.
First, identifying lymphomatous cells in the bone marrow may aid
in the diagnosis of lymphoma if extramedullary sites are not avail-
able or not accessible for histopathological examination. Second,
bone marrow assessment is a crucial part of the Ann Arbor system,
which is the most commonly used staging tool in lymphoma, and in
which bone marrow involvement implies the highest disease stage
(stage IV) [1–3]. Bone marrow involvement is, either directly or indi-
rectly through the Ann Arbor system, also an important factor in most
clinical risk stratiﬁcation indices, including the International Prognostic
Score (IPS) for advanced Hodgkin lymphoma [4], the International
Prognostic Index (IPI) and its successors for aggressive non-Hodgkin
lymphoma and diffuse large B-cell lymphoma (DLBCL) [5–7], and the
Follicular Lymphoma International Prognostic Index (FLIPI) and new
FLIPI 2 for follicular lymphoma [8,9]. Importantly, it should be realized
that these clinical risk stratiﬁcation indices only used lymphoma-
positive bone marrow biopsy (BMB) specimens as proof of bone mar-
row involvement [4–8], and not bone marrow involvement as detected
by 18F-ﬂuoro-2-deoxy-D-glucose positron emission tomography (FDG-
PET). Third, the presence of bone marrow involvement may change
the choice of therapy, particularly in patients who were thought tod Nuclear Medicine, University
cht, The Netherlands. Tel.: +31
.have early stage disease only before bone marrow evaluation. Fourth,
bone marrow involvement has been reported to be an important pre-
dictor of occurrence of an infusion-related reaction following rituximab
administration [10]. Fifth, knowing all sites of lymphomatous involve-
ment, including bone marrow sites, allows monitoring the effects of
therapy [11].
BMB has been the established method for bone marrow evaluation
in various diseases, including lymphoma, for many decades [12,13].
Meanwhile, FDG-PET has become an establishedmethod for lymphoma
staging, and it may potentially be a non-invasive alternative or com-
plementary method to BMB. However, its clinical value in the evalu-
ation of the bone marrow in lymphoma is still under debate and
investigation. The purpose of this scientiﬁc communication is to pro-
vide an evidence-based overview about the opportunities and limi-
tations of BMB and FDG-PET in the evaluation of the bone marrow
in patients with lymphoma. Although bone marrow MRI is another
potentially useful method in lymphoma, it will not be discussed in
the article because its use is not widespread and evidence on its util-
ity is still limited. This article will ﬁrst review the basic properties,
opportunities and limitations of BMB and bone marrow FDG-PET,
and will then focus on the clinical utility of BMB and bone marrow
FDG-PET in three major lymphoma subtypes, including Hodgkin
lymphoma, DLBCL, and follicular lymphoma.
2. BMB
The main advantage of BMB is the acquisition of histologic material.
A positive BMB is considered as a deﬁnitive proof of bone marrow
involvement. It can also show discordance in morphology between
lymphomatous cells in the bone marrow and lymphomatous cells in
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in follicular lymphoma andDLBCL [14,15]. BMBmay also be useful in es-
tablishing the diagnosis of lymphoma if histologic examination of
extramedullary tissue is inconclusive or not possible. Finally, histologic
examination of the bone marrowmay incidentally result in the diagno-
sis of another, non-lymphoma bone marrow disease.
One major disadvantage of BMB is its invasiveness. It is a stressful
and painful procedure, despite the use of local anesthesia. In a series
of 235 adult patients, about 70% of patients experienced procedure-
related pain, with one-third of these patients indicating severe pain
[16]. Sedation with drugs such as lorazepam, midazolam or diazepam
is often administered in addition to local anesthesia, which has been re-
ported to reduce anxiety, pain perception and result in retrograde am-
nesia for the procedure in many patients [17–19]. However, apart
from these beneﬁcial effects, performing BMB under sedation has draw-
backs, like requirement of additional staff and equipment and prolonga-
tion of hospital stay. In a series of 19,259 procedures from 63 hospitals,
with 13,147 being a combination of bone marrow aspiration and tre-
phine biopsy and 6112 aspirates without trephine biopsy, 16 adverse
events were reported, representing 0.08% of total reported procedures
[20]. The major adverse event was hemorrhage, which comprised 11
of the 16 adverse events [20]. Although infrequent, adverse events
were associated with signiﬁcant morbidity and three were judged as
very serious [20]. Another major shortcoming is that BMB assesses
only a very small portion of the entire bone marrow, as a result of
which focal bone marrow involvement may be missed (Fig. 1). This
has been demonstrated by previous studies in which bilateral or paired
ipsilateral BMBs were performed in the same patients, and in which
only one bone marrow specimen was positive for lymphoma in a con-
siderable proportion of patients, ranging between 10–60% [21–24].
Obtaining multiple tissue samples from different locations improves
the diagnostic yield of BMB [21–24], but obviously increases patient
burden and complication rate. Due to the risk of sampling errors, it
should be realized that a negative BMB after completion of therapy can-
not reliably exclude residual bonemarrow involvement either. The sub-
optimal sensitivity of BMB also indicates the need to carefully interpret
previously reported BMB-based incidences of bone marrow involve-
ment in different lymphoma subtypes, since these percentages areFig. 1.A 68-year-oldmanwith extensive FDG-avid bonemarrow lesions, demonstrated at
coronal maximum intensity projection FDG-PET (A). Blind BMB of the right posterior iliac
crest was negative for lymphoma. The large destructive left sacral lesion (A, arrow), also
demonstrated at axial CT (B, arrow) and axial FDG-PET/CT (C, arrow), was therefore
biopsied using CT guidance (D). Histopathologic examination revealed DLBCL.underestimated. It also underlines the importance of refraining from
using BMB as reference standard in imaging studies to calculate false
positives and true negatives on a patient level, because a negative
BMB does not exclude bone marrow involvement [25]. Yet another
disadvantage of BMB is that marrow tissue should be ﬁxed and
decalciﬁed before it can be histologically examined [26], which is a
time-consuming procedure that may cause delay in diagnostic workup
and postponement of treatment initiation. The aforementioned disad-
vantages of BMB show the importance of refraining from performing a
BMB in patients who are at very low risk of having bone marrow in-
volvement (based on epidemiological data, clinical prediction rules, or
imaging techniques) or in patients in whom the bone marrow result
will not have any (therapeutic) consequences.
3. Bone marrow FDG-PET
Malignant lesions of Hodgkin lymphoma and aggressive lymphomas
located outside the bone marrow are generally FDG-avid, and most in-
dolent lymphomas also demonstrate an increased FDG uptake [27].
Therefore, FDG-PET has been proposed as a potentially useful method
for bone marrow assessment in lymphoma. A major advantage of
FDG-PET is that it allows visualization of the entire marrow, whereas
bonemarrowassessment byBMB is restricted to the iliac crest/site of bi-
opsy (Fig. 1). Under normal conditions the bone marrow shows homo-
geneously low uptake of FDG, with the bone marrow appearing less
intense than the liver [28]. The distribution of FDG throughout the skel-
eton follows that of the redmarrow [29,30], which changes during nor-
mal aging [29–31]. There are no prospectively validated criteria for
assessing lymphomatous bone marrow lesions at FDG-PET. The most
previously reported studies on this topic consider focal bone marrow
FDG uptake exceeding liver FDG uptake as indicative of bone marrow
involvement [32,33]. This criterion is also reported in the recently pub-
lished Recommendations for initial evaluation, staging, and response as-
sessment of Hodgkin and non-Hodgkin lymphoma [34,35], whereas less
consensus has been reached on the interpretation of homogeneously,
diffusely increased bonemarrow FDGuptake [34–39] (see the later sec-
tion). Unfortunately, the determination of the actual diagnostic value of
bone marrow FDG-PET is difﬁcult, since studies that perform FDG-PET
guided targeted biopsies are scarce and often only iliac crest BMBs are
available for conﬁrmation. However, lesions located outside the iliac
crest will be missed by BMB, which will erroneously result in false-
positive and true-negative bone marrow FDG-PET cases if only BMB is
used as reference standard [25]. In other words, BMB is not a suitable
reference standard to calculate the speciﬁcity of bone marrow FDG-
PET at a patient level. Multiple studies have tried to overcome this prob-
lem by using follow-up FDG-PET scans as part of their reference stan-
dard and considering FDG-avid bone marrow lesions at baseline as
true-positive when these lesions disappear during or after therapy.
However, benign bone marrow lesions and even active physiological
red marrow may also show (either focally or diffusely) increased bone
marrow FDG uptake that can decline after therapy [36,40–46]. Thus,
follow-up FDG-PET examinations may not be reliable for this purpose.
4. Hodgkin lymphoma
4.1. BMB
Bone marrow involvement is rare in Hodgkin lymphoma, with a
BMB-based incidence varying between 4% and 14% [47,48]. In clinical/
radiological stage IA or IIA disease (without taking into account BMB re-
sults), the incidence of bone marrow involvement has been reported to
be even lower or close to, if not, 0% [48]. In linewith the low incidence of
bone marrow involvement in this disease, the Cotswolds report on the
evaluation and staging of Hodgkin lymphoma that was issued in 1989
(far before FDG-PET was routinely implemented in clinical practice),
already recommended to restrict BMB to patients with computed
419H.J.A. Adams et al. / Blood Reviews 29 (2015) 417–425tomography (CT)-based stage III/IV disease or stage II disease with ad-
verse unfavorable factors, and only if a positive ﬁnding would change
treatment planning [49]. Prediction rules have been developed to esti-
mate the risk of bone marrow involvement, in order to avoid BMB in
certain subgroups of patients. Based on a series of 826Hodgkin lympho-
ma patients, enhanced with a validation group of another 654 patients,
it was reported that patients with low risk (stage IA/IIA without anemia
and leukopenia; stage IA/IIA, younger than 35 years, with either anemia
or leukopenia but no inguinal/iliac involvement; and stage IIIA/IVA
without any of these four risk factors) do not require BMB [47]. Thus,
evenwithout the use of bonemarrow FDG-PET, the correlation between
clinical/radiological Ann Arbor stage and the prevalence of BMB-proven
bone marrow involvement, and the availability of efﬁcient clinical pre-
diction rules allows sparing BMB in many Hodgkin lymphoma patients.
Nevertheless, at least until recently, therewas still a lot of variationwith
regard to the use or omission of BMB in Hodgkin lymphoma patients in
routine clinical practice [50].
Of interest, BMB-based lymphomatous involvement has not been
proven to be amajor adverse predictor of outcome in Hodgkin lympho-
ma. In the cohort on the development of the IPS in advanced stage
Hodgkin lymphoma, progression-free survival (PFS) and overall surviv-
al (OS) in 614 patients with BMB-proven bone marrow involvement
(60% and 70%, respectively) were not signiﬁcantly different from those
in 1351 patients without bone marrow involvement according to BMB
(61% and 74%, respectively) [4]. This indicates that omission of BMB
will not result in a major decline in prognostic power of the IPS in pa-
tients with advanced stage disease [4]. In early stage disease, the inci-
dence of bone marrow involvement is extremely low, and the
prognostic value of BMB in this subpopulation has therefore not been
well documented.4.2. Bone marrow FDG-PET
FDG-PET ismuchmore frequently positive for bonemarrow involve-
ment than BMB in patients with Hodgkin lymphoma (Table 1), and has
therefore been proposed as a very sensitive method for the detection of
bonemarrow involvement thatmay surpass the diagnostic yield of BMB
[34,35]. However, multiple studies have shown that a considerable pro-
portion of Hodgkin lymphomapatients with a positive BMB do not have
pathological FDG uptake in the bone marrow (Table 1). Nevertheless,
current guidelines do not recommend to routinely perform BMB in all
patients.[34,35,51]. Regardless of the sensitivity of bone marrow FDG-
PET, it is more important to consider the therapeutic consequences of
omitting BMB in patients who actually have lymphomatous bone mar-
row involvement. El-Galaly et al. [52] included 454 Hodgkin lymphoma
patients and reported that BMB did not change treatment planning in
their series since no positive BMBs in FDG-PET/CT-assessed stage I–II
disease were observed. It should be noted that positive BMBs are also
rarely found in CT-based stage I–II disease [48,49]. Therefore, it is un-
likely that bone marrow FDG-PET will have any substantial additionalTable 1
Diagnostic value of FDG-PET for detecting bone marrow involvement in Hodgkin lymphoma u
Study (year) No. of patients included No. of patients BMB + No o
Weiler-Sagie et al. [72] (2014) 330 9 (2.7%) 57 (
Cortés-Romera et al. [73] (2013) 63 6 (9.5%) 15 (
Agrawal et al. [74] (2013) 31 5 (16.1%) 7 (
Muzahir et al. [75] (2012) 122 11 (9.0%) 26 (
El-Galaly et al. [52] (2012) 454 27 (5.9%) 82 (
Pelosi et al. [76] (2011) 82 6 (7.3%) 22 (
Mittal et al. [77] (2011) 20 2 (10%) 5 (
Cheng et al. [78] (2011) 31 2 (6.5%) 4 (
Moulin-Romsee et al. [79] (2010) 83 7 (8.4%) 11 (
Ngeow et al. [80] (2009) 21 1 (4.8%) 3 (
a Patients with diffusely increased bone marrow FDG uptake were considered negative for bvalue in terms of treatment consequences in patients who have already
undergone either FDG-PET/CT or CT only for extramedullary staging.
Data on the prognostic impact of bone marrow FDG-PET in Hodgkin
lymphoma are scarce. El-Galaly reported that in a group of 414 cases,
patients with skeletal lesions at FDG-PET had signiﬁcantly worse PFS
and OS (63% and 77%, respectively) than those without (85% and
91%, respectively). However, on multivariate analysis, FDG-PET-
based bone marrow involvement was not an independent predictor
of outcome after correcting for the risk factors age ≥45 years and
Eastern Cooperative Oncology Group performance score ≥2. Bone
marrow FDG-PET/CT ﬁndings are not incorporated in any current
risk stratiﬁcation index for Hodgkin lymphoma, including the IPS
for advanced Hodgkin lymphoma [4].
5. DLBCL
5.1. BMB
DLBCL has a reported BMB-based incidence of bonemarrow involve-
ment of around 11–17% [53–55]. In early stage DLBCL (i.e. stage I–II dis-
ease), this incidence drops to 3.6% [56]. In a study of 120 patients with
early stage DLBCL who had normal hemoglobin levels, normal white
blood cell count, and no bulky disease, only one patient (0.83%) had
bone marrow involvement [56]. The absence of all three factors yielded
a negative predictive value of 99.2% [56]. These results suggest that BMB
may safely be omitted in selected patients with early stage DLBCL [56].
In another series of 113 DLBCL patients, 0 of 17 patients (0%) with
stage I disease had a positive BMB, 1 of 10 patients (10%) with stage II
disease had a positive BMB, 6 of 27 patients (22.2%) with stage III dis-
ease had a positive BMB, and 11 of 59 patients (18.6%) with stage IV dis-
ease had a positive BMB [57], which conﬁrms the need to reconsider the
need for routine BMB in early stage disease. In the same study, BMB
ﬁndings changed the National Comprehensive Cancer Network IPI [7]
(which is the best validated risk stratiﬁcation model in DLBCL that is
treated with rituximab, cyclophosphamide, hydroxydaunorubicin,
vincristine and prednisone [R-CHOP]) in 9 of 113 patients (8.0%)
[57]. Five patients were upstaged from low-intermediate to high-
intermediate risk, and four patients were upstaged from high-
intermediate to high risk. However, BMB ﬁndings changed treatment
planning in none of the 113 patients. These ﬁndings support the omis-
sion of BMB from routine staging of newly diagnosed DLBCL in the cur-
rent risk stratiﬁcation and treatment era, evenwhen bonemarrowFDG-
PET is not performed [57]. Performing repeat BMBs at the end of treat-
ment in DLBCL patients with bone marrow involvement at baseline is
recommended by current guidelines [11,35,58]. However, its additional
value in this setting is likely to be low, since a recent study showed that
only 1 of 34 (2.9%) patients with lymphoma-positive BMBs at baseline
had residual lymphomatous deposits in the BMB after treatment [59].
Other than lymphoma detection, BMB with subsequent histologic ex-
amination may also characterize lymphoma cells in the bone marrow.
Lymphoma cells in the bone marrow in DLBCL patients can besing iliac crest BMB as reference standard.
f patients FDG-PET +a (%) Sensitivity of focally increased bone marrow FDG uptake
17.3%) 7/9 (77.8%)
23.8%) 6/6 (100%)
22.6) 4/5 (80%)
21.3%) 9/11 (81.8%)
18.1%) 23/27 (85.2%)
26.8%) 6/12 (50%)
25%) 2/2 (100%)
12.9%) 2/2 (100%)
13.3% 7/7 (100%)
14.3%) 1/1 (100%)
one marrow involvement in Hodgkin lymphoma.
420 H.J.A. Adams et al. / Blood Reviews 29 (2015) 417–425characterized as large cells (i.e. concordant bonemarrow involvement)
or as small cells (i.e. discordant bonemarrow involvement). Important-
ly, previous studies have shown that concordant bonemarrow involve-
ment is an independent and strong predictor of worse outcome, while
the prognosis of patients with discordant bone marrow involvement
nearly equals that of patients without bone marrow involvement [15,
54,55,60].
5.2. Bone marrow FDG-PET
Although the incidence of BMB-based bone marrow involvement is
relatively low in DLBCL [53–56,60], bone marrow involvement accord-
ing to FDG-PET is relatively common, with a reported incidence be-
tween 24–29% in the majority of studies (Table 2). This has resulted in
the notion that FDG-PET may have a high sensitivity for the detection
of bone marrow involvement in DLBCL, surpassing that of BMB [37].
Consequently, the recently published Recommendations for initial eval-
uation, staging, and response assessment of Hodgkin and non-Hodgkin
lymphoma stated that focal bonemarrow FDGuptake is highly sensitive
for lymphomatous bonemarrow involvement in aggressive lymphoma,
including DLBCL, and may obviate the need for BMB [34,35]. However,
the actual sensitivity of FDG-PET for diagnosing bone marrowTable 2
Diagnostic value of FDG-PET for detecting bonemarrow involvement inDLBCL using iliac crest B
and FDG-PET, and histopathological characteristics of positive BMBs that were missed at FDG-
Study (year) No. of
patients
included
No. of
patients
BMB+ (%)
No. of
patients
FDG-PET+a
No. of patients
with diffusely
increased FDG
uptake
Sensitivi
focally a
increase
marrow
Cerci et al. [39] (2014) 327 35 (10.7%) 86 (26.3%) 18 25/35 (7
Adams et al. [62] (2014) 78 16 (20.5%) 34 (43.6%) 4 11/16 (6
Cortés-Romera et al. [73]
(2014)
84 16 (19.0%) 24 (28.6%) 4 15/16 (9
Khan et al. [37] (2013) 130 14 (10.7%) 33 (25.4%) 2 12/14 (8
Berthet et al. [38] (2013) 133 8 (6.0%) 32 (24.1%) 11 6/8 (7
Hong et al. [63] (2013) 89 14 (15.7%) 17 (19.1%) NRc 7/14 (5
Ngeow et al. [80] (2009) 55 6 (10.9%) 5 (9.1%) NR 3/6 (5
Ribrag et al. [81] (2008) 43 5 (11.6%) 8 (18.6%) 0 4/5 (8
Notes:
+ Positive.
− Negative.
Abbreviations:
NR: Not reported.
a Focally and diffusely increased bone marrow FDG uptake were considered positive at FDG
b At univariate analysis.
c This study used an alternative deﬁnition of diffuse bonemarrow FDG uptake, namely: heter
more deﬁnitely hypermetabolic areas.involvement is currently under debate and is highly inﬂuenced by the
criteria used for the deﬁnition of bone marrow involvement. A recent
meta-analysis on the diagnostic value of FDG-PET for detecting bone
marrow involvement in DLBCL reported high sensitivity and speciﬁcity
for FDG-PET ranging from 70.8% to 95.8% and 99.0%–100%, with pooled
estimates of 88.7% and 99.8% respectively [33]. The studies included in
that meta-analysis used both BMB and decrease/disappearance of
bone marrow FDG uptake on follow-up FDG-PET scans as proof of
bone marrow involvement, but the latter may not be sufﬁcient proof
of bone marrow involvement at baseline, as discussed previously.
Therefore, the actual diagnostic value of bonemarrow FDG-PET is likely
to be lower in DLBCL.When only the iliac crest BMB is used as reference
standard (without using follow-up FDG-PET scans), the sensitivity of
FDG-PET decreases to 50–93.8% when both focally and diffusely in-
creased bone marrow FDG uptake are regarded as positive for bone
marrow involvement, and to 43.8–75% if only focally increased bone
marrow FDG uptake is regarded as positive for bone marrow involve-
ment (Table 2). Importantly, in all these studies, BMB of the iliac crest
was used as reference standard for the assessment of the sensitivity of
bonemarrow FDG-PET at a patient level.When a spatially matched cor-
relation is performed, i.e. a direct comparison between FDG-PET and
BMB ﬁndings at the iliac crest, the sensitivity of bone marrow FDG-MBas reference standard, prognostic value of bonemarrow involvement according to BMB
PET.
ty of
nd diffusely
d bone
FDG uptake
Sensitivity of
focally increased
bone marrow
FDG uptake
Signiﬁcant
adverse
prognosis
BMB+ vs.
BMB−b
Signiﬁcant
adverse
prognosis
FDG-PET+ vs.
FDG-PET−b
Histopathological
characteristics of
BMBs+ missed
by FDG-PET
1.4%) 21/35 (60.0%) Yes NR, but unlikely 6× large-cell
involvement
b10%
2× large cell
involvement
N10%
2× small-cell
involvement
8.8%) 7/16 (43.8%) Yes No 3× large cell
involvement
(10%, 40%, and 40%)
2× small cell
involvement
(3% and 20%)
3.8%) 11/16 (68.8%) NR NR NR
5.7%) 10/14 (71.4%) Yes No 2× large cell (≈10%)
5%) 6/8 (75%) Yes Yes NR
0%) NRc Yes No 1× large cell,
low-volume
involvement
3× large cell,
high-volume
involvement
2× small cell,
low-volume
involvement
1× small cell,
high-volume
involvement
0%) NR NR NR NR
0%) NR NR NR 1× small cell
involvement
-PET.
ogeneously widespread uptake in hematopoietic bonemarrow or bony sites with three or
421H.J.A. Adams et al. / Blood Reviews 29 (2015) 417–425PET has been reported to be as low as 14.3% [61]. Of note, studies have
also shown that both large-cell (concordant) and small-cell (discor-
dant) bone marrow involvement can be missed by FDG-PET (Table 2).
Another important topic is that although it has been proven that pa-
tients with BMB-based bone marrow involvement have a considerably
worse outcome [54,60], this does not apply to FDG-PET-based bone
marrow involvement. Of the four published studies on the prognostic
value of bone marrow FDG-PET in DLBCL [37,38,62,63], three reported
that FDG-PET-based bonemarrow involvement does not have any prog-
nostic value at all [37,62,63]. The only study that reported FDG-PET-
based bone marrow involvement to have prognostic value clearly
showed that bone marrow FDG-PET was prognostically inferior to
BMB [38]. That particular study reported bone marrow FDG-PET nega-
tive patients to have 2-year PFS and OS of 84.5% and 88.5%, and bone
marrow FDG-PET positive patients to have PFS and OS of 62.5% and
76.1%, respectively [38]. However, the 2-year PFS and OS of BMB-
negative patients were 82.1% and 87.2%, and those of BMB-positive
patients were 37.5% and 62.5%, respectively, which clearly shows that
BMB is better at selecting patients with a worse prognosis [38]. It has
been speculated that the absent or weak prognostic implications of
bone marrow FDG-PET may be due to the detection of small and
prognostically irrelevant lymphoma deposits, in contrast to BMB that
is more likely to be positive only in the case of extensive marrow in-
volvement [64]. However, it has recently been proven that quantiﬁca-
tion of the (metabolic) volume of bone marrow lesions at FDG-PET
does not improve prognostication either [44]. FDG-PET-based bone
marrow involvement has not been incorporated in the recently im-
proved (National Comprehensive Cancer Network) IPI, and this prog-
nostic index explicitly states that only histologically established bone
marrow involvement, and not imaging-based bone marrow involve-
ment should be used for risk stratiﬁcation [7].
6. Follicular lymphoma
6.1. BMB
Bone marrow involvement is very common in follicular lymphoma
[65], with up to 50% of patients having a positive BMB [66]. Staging is
particularly important in the small proportion of patients with limited
non-bulky Ann Arbor stage I–II disease (10–15%), in whom involved-
ﬁeld radiation therapy is the preferred treatment with curative poten-
tial provided bone marrow involvement is absent [67]. Therefore, the
National Comprehensive Cancer Network guidelines [68] recommend
bilateral BMB if curative therapy is considered, but state that BMB may
be deferred if observation is the initial therapy. Other guidelines, how-
ever, recommend performing unilateral BMB in all patients with follicu-
lar lymphoma [34,35,67]. Although rare, BMB results may sometimes
reveal involvement by an aggressive lymphoma and consequently re-
sult in rapid treatment initiation [14,67]. The prognostic role of positive
BMBs in follicular lymphoma is well deﬁned. The cohort that was used
for the development of the FLIPI included4016 patientswhounderwent
BMB. Patientswith a positive BMB had a signiﬁcantly reduced 5-year OS
(65.7% vs. 75.6%) and 10-year OS (40.4% vs. 56.2%) compared to patients
with a negative BMB [8]. Bone marrow involvement remained anTable 3
Diagnostic value of FDG-PET for detecting bone marrow involvement in follicular lymphoma u
Study (year) No. of patients
included
No of patients
BMB+
No of patients
FDG-PET+a
Luminari et al. [69] (2013) 142 70 (49.3%) 34 (23.9%)
Le Dortz et al. [82] (2010) 45 20 (44.4%) 13 (28.9%)
Wohrer et al. [83] (2006) 64 24 (37.5%) 13 (20.3%)
Abbreviations:
NR: Not reported.
a Focally and diffusely increased FDG-uptake were considered positive at FDG-PET.independent predictor of outcome in the multivariate analysis (P =
0.001) and was therefore incorporated into the FLIPI [8]. Similar results
were observed in the cohort of the FLIPI 2 studywhich included 832 pa-
tients and showed that bonemarrow statuswas an independent predic-
tor of outcome, thus justifying the inclusion of BMB ﬁndings in that
prognostic index [9].
6.2. Bone marrow FDG-PET
In contrast to the high BMB-based incidence of bone marrow in-
volvement, pathologically increased bone marrow FDG uptake has
been reported to occur in only 20–25% of follicular lymphoma cases,
with a considerable proportion of these cases having diffusely increased
bone marrow FDG uptake (Table 3). Unfortunately, the detectability of
bone marrow involvement by FDG-PET is low in follicular lymphoma,
with reported sensitivities ranging between 20.3–28.9% (Table 3).
Thus, bone marrow FDG-PET cannot replace BMB in follicular lympho-
ma. However, difﬁculty arises as how to interpret bonemarrow involve-
ment according to FDG-PET in patients with a negative BMB. There are
currently no studies that evaluated the prognostic potential of bone
marrow FDG-PET in follicular lymphoma, and bone marrow FDG-PET
ﬁndings are not part of the FLIPI or FLIPI 2 [8,69]. Therefore, at present
it is controversial to classify patients with positive bone marrow FDG-
PET ﬁndings as having stage IV disease without histologic proof of
bone marrow involvement.
7. Diffusely increased bone marrow FDG uptake
Diffusely increased bonemarrow FDG uptake, usually deﬁned as ho-
mogeneous FDG uptake of the entire axial skeleton that exceeds liver
FDG uptake (Fig. 2), is a well-known phenomenon in patients treated
with hematopoietic growth factors following chemotherapy [70,71],
but is relatively uncommon in newly diagnosed and recently untreated
lymphoma patients [37,39,62]. This particular phenomenon deserves
special attention to correctly interpret its clinical relevance. At diagno-
sis, its incidence has been reported to range between 5.2–9.3% in Hodg-
kin lymphoma, between 3.8–8.3% in DLBCL, and between 11.1–14.0% in
follicular lymphoma (Table 4). In a study of 23 recently untreated lym-
phoma patients with diffusely increased bone marrow FDG uptake,
91.3% were anemic, 81.0% had elevated C-reactive protein levels,
47.8% had leukocytosis, 39.1% had thrombocytopenia and 21.7% had
thrombocytosis [36]. Although the relationship between diffusely in-
creased bone marrow FDG uptake and laboratory alterations suggests
that this phenomenon may be related to a reactive bone marrow pro-
cess or altered blood composition rather than lymphomatous bonemar-
row involvement, this does not appear to be the case in all lymphoma
subtypes. In Hodgkin lymphoma, BMBs of patients with diffusely in-
creased bone marrow FDG uptake are usually negative for lymphoma,
but in non-Hodgkin lymphomas these results are not consistent
(Table 4). Two of four studies on this topic in DLBCL reported that
BMBs of all patients with diffusely increased bone marrow FDG uptake
showed lymphomatous involvement [37,62], whereas two other stud-
ies on this topic in DLBCL reported BMB to be negative in the majority
of these cases [38,39]. Of note, it was not consistently reported in allsing iliac crest BMB as reference standard.
No. of patients with
diffusely increased
bone marrow FDG uptake
Sensitivity of focally and
diffusely increased bone
marrow FDG uptake
Sensitivity of focally
increased bone marrow
FDG uptake
NR 24/70 (34.3%) NR
8 8/20 (40%) 3/20 (15%)
4 13/24 (54.2%) 4/24 (16.7%)
Fig. 2. Pattern of non-focal, diffusely increased bonemarrow FDG uptake (exceeding liver
FDG uptake).
Table 5
General advantages/applications and disadvantages/limitations of BMB and FDG-PET in
the evaluation of the bone marrow.
Advantages/applications Disadvantages/limitations
BMB – Deﬁnitive proof of bone
marrow involvement
– Possibility to characterize
and quantify lymphomatous
cells in the bone marrow
– Possibility to (occasionally)
diagnose other bone marrow
alterations/diseases
– Incorporated in established
clinical risk stratiﬁcation indices
– Invasive
– Sampling errors
– Time consuming procedure
(decalciﬁcation)
FDG-PET – Whole-body bone marrow
evaluation
– Simultaneous staging of
extramedullary disease
– Non-invasive
– May direct targeted biopsies
– Not every FDG-avid
bone marrow abnormality
represents lymphoma
– Lack of histologic material
– Use of ionizing radiation
422 H.J.A. Adams et al. / Blood Reviews 29 (2015) 417–425studies whether or not therapies such as hematopoietic growth factor
administration were used prior to FDG-PET acquisition which could be
an explanation for the different results.Moreover, clear criteria to deﬁne
diffusely increased bone marrow FDG uptake are not yet established,
and variability in the interpretation of FDG-PET scans among studies
might be another explanation for the discrepant results. In follicular
lymphoma, the limited data show that BMBs are positive for lymphoma
in the majority of cases with diffusely increased bone marrow FDG up-
take (Table 4).Table 4
Incidence of and number of positive bone marrow biopsies in patients with diffusely increased
Study (year) No. of patients included No. of
bone m
Hodgkin lymphoma
Adams et al. [36] (2014) 75 7/75
Muzahir et al. [75] (2012) 122 11/122
El-Galaly et al. [52] (2012) 454 24/454
Moulin-Romsee et al. [79] (2010) 83 5/83
DLBCL
Cerci et al. [39] (2014) 327 18/327
Adams et al. [62] (2014) 78 4/78 (5
Khan et al. [37] (2013) 130 2/130 (
Berthet et al. [38] (2013) 133 11/133
Follicular lymphoma
Adams et al. [36] (2014) NR 3
Le Dortz et al. [82] (2010) 45 5/45 (1
Wohrer et al. [83] (2006) 64 9/64 (1
Abbreviations:
NR: Not reported.
a 3 patients were diagnosed with diffusely increased bone marrow FDG uptake in combinat
b Including 1 case of homogeneous and 4 cases of slightly heterogeneous bone marrow FDG
c Including 2 cases of homogeneous and 7 cases of slightly heterogeneous bone marrow FDG8. Summary
BMB is invasive and provides histologic examination of a small bone
marrow sample, whereas FDG-PET is non-invasive and allows visualiza-
tion of the entire bone marrow but lacks histologic material. Table 5
summarizes the general advantages/applications and disadvantages/
limitations of BMB and FDG-PET in the evaluation of the bone marrow.
In Hodgkin lymphoma, the combination of the very low incidence of
bone marrow involvement in early stage disease, and the lack of treat-
ment consequences if bonemarrow involvement is missed in advanced
stage disease, allows omitting BMB if a FDG-PET staging examination
has been performed. This notion likely also holds true if CT only is per-
formed for staging. In DLBCL, the diagnostic value of FDG-PET to identify
patients with involved BMBs is suboptimal and although bone marrow
involvement at BMBhas been established as an important adverse prog-
nostic factor, the prognostic consequences of bonemarrow involvement
at FDG-PET are absent. Thus, most evidence suggests that FDG-PET can-
not replace BMB. On the other hand, the additional value of BMB to the
standard diagnosticwork-up inDLBCL is also limited in terms of therapy
planning. In follicular lymphoma, FDG-PET is insufﬁciently sensitive for
bone marrow involvement, and BMB remains recommended, particu-
larly when potentially curative therapy is considered. Table 6 summa-
rizes the current evidence-based clinical utility of bone marrow FDG-bone marrow FDG uptake in different lymphoma subtypes.
patients with diffusely increased
arrow FDG uptake (%)
No. of patients with lymphoma-positive
BMBs (%)
(9.3%) 0/7 (0%)
(9.0%) 2/11 (18.2%)
(5.2%) 0/24 (0%)
(6.0%) 0/5 (0%)
(5.5%) 4/18 (22.2%)
.1%) 4/4 (100%)
1.5%) or 5/130 (3.8%)a 2/2 (100%) or 5/5 (100%)
(8.3%) 1/11 (9.0%)
3/3 (100%)
1.1%)b 5/5 (100%)
4.0%)c 9/9 (100%)
ion with focally increased bone marrow FDG uptake.
uptake.
uptake.
Table 6
Current evidence-based clinical utility of BMB and bone marrow FDG-PET in Hodgkin lymphoma, DLBCL, and follicular lymphoma.
Hodgkin lymphoma DLBCL Follicular lymphoma
Incidence bone marrow involvement
according to BMBa
4–14%, [47,48] approaching 0%
in clinical stage IA–IIA disease, [48]
11–17%, [53,54,60] 3.6% in stage
I–II disease
40–50% [8,9,66]
Therapeutic impact BMB Absent/negligible Absent/negligible Important in limited non-bulky
Ann Arbor stage I–II disease
Independent prognostic impact BMB No/weak [4,84] – Concordant bone marrow
involvement: strong
– Discordant bone marrow
involvement: weak [7,54,60]
Strong [8,9]
Incidence bone marrow involvement
according to FDG-PET
12.9–23.8%b Usually 24–29%, reported range:
9.1–43.6%c
20–29%d
Sensitivity of FDG-PET to detect BMB+ Reasonableb Suboptimalc Lowd
Independent prognostic impact of bone
marrow FDG-PET
No [85] No/weak [37–39,62]c Unknown
BMB necessary according to recent
international guidelines?
No [34,35,51] Debatable, depending on FDG-PET
ﬁndings and clinical situation [34,35]
Yes [34,35,67]/may be deferred if
observation is initial therapy [68]
a Based on BMB studies.
b See Table 1.
c See Table 2.
d See Table 3.
423H.J.A. Adams et al. / Blood Reviews 29 (2015) 417–425PET in Hodgkin lymphoma, DLBCL, and follicular lymphoma. Future
studies (for example large-scale studies that perform FDG-PET guided
BMBs) are needed to solve existing controversies and to ﬁll in knowl-
edge gaps on the role of bone marrow FDG-PET in lymphoma.
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